Pfizer will run out of penicillin doses that treat common infections like syphilis, strep throat, and others

Per Bloomberg

Pfizer has recently released a letter detailing how the pharmaceutical giant is expected to run out of "several doses of penicillin." This comes as the company says that the shortage is due to supply interruptions.

The type of penicillin that Pfizer will run out of is used to treat some infections like syphilis and strep throat. Specifically, the company expects Bicillin L-A, a syphilis drug in children's doses, is expected to run out by the end of June.

The larger dose of the Bicillin L-A is now going to be the focus of the company. This type of penicillin is reportedly for pregnant people with syphilis.  

The Bicillin C-R, which treats other bacterial infections, is expected by the company to run out on September 30.

Pfizer's letter detailed the company's take on the shortage and how it was due to supply interruptions.

“The supply interruption is the result of a complex combination of factors including significant increases in demand, due to an increase in syphilis infection rates as well as competitive shortages,”

In January, Pfizer reportedly had Twitter censor users tweeting at them regarding inquiries about generic low-cost vaccines. This information came from Lee Fang of Twitter Files.

It was revealed that BioNTech emailed Twitter directly in order to ask its moderators to censor the tweets directed at them, asking whether the company would share its intellectual property.

It was revealed that Scott Gottlier emailed a top lobbyist in Twitter's Washington Office regarding Covid vaccine comments. Scott Gottlieb was a Pfizer board person who spotted a tweet by Dr. Brett Giroir explaining the difference between vaccine protection and natural immunity, saying the latter was more effective.

Dr. Gottlieb reportedly messaged Twitter to share concerns regarding the post. Dr. Brett Giroir was a physician.

See flow at unusualwhales.com/flow.

Other News:

Resources:

Bloomberg

tastytrade logo+
Get the best broker for options trading and earn Unusual Whales discounted! in cash with an eligible account deposit at tastytrade. Get an Unusual Whales bonus when you deposit $2000. Offer expires 3/31/25. Certain restrictions, terms and conditions apply.
Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.